U.S. Markets open in 7 hrs 32 mins
  • S&P Futures

    3,859.50
    +11.25 (+0.29%)
     
  • Dow Futures

    31,097.00
    +84.00 (+0.27%)
     
  • Nasdaq Futures

    11,929.50
    +49.25 (+0.41%)
     
  • Russell 2000 Futures

    1,735.20
    +6.60 (+0.38%)
     
  • Crude Oil

    98.79
    +0.26 (+0.26%)
     
  • Gold

    1,745.40
    +8.90 (+0.51%)
     
  • Silver

    19.30
    +0.14 (+0.71%)
     
  • EUR/USD

    1.0220
    +0.0035 (+0.3475%)
     
  • 10-Yr Bond

    2.9130
    0.0000 (0.00%)
     
  • Vix

    26.82
    -0.72 (-2.61%)
     
  • GBP/USD

    1.1954
    +0.0032 (+0.2726%)
     
  • USD/JPY

    135.8830
    -0.0320 (-0.0235%)
     
  • BTC-USD

    20,309.23
    +233.89 (+1.17%)
     
  • CMC Crypto 200

    440.06
    +4.54 (+1.04%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,439.96
    +332.31 (+1.27%)
     

Investors in Avalo Therapeutics (NASDAQ:AVTX) have unfortunately lost 90% over the last three years

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Over the last month the Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been much stronger than before, rebounding by 54%. But that is meagre solace in the face of the shocking decline over three years. In that time the share price has melted like a snowball in the desert, down 90%. So it's about time shareholders saw some gains. Of course the real question is whether the business can sustain a turnaround. We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.

Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.

See our latest analysis for Avalo Therapeutics

Avalo Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Over three years, Avalo Therapeutics grew revenue at 19% per year. That's a pretty good rate of top-line growth. So it's hard to believe the share price decline of 24% per year is due to the revenue. It could be that the losses were much larger than expected. This is exactly why investors need to diversify - even when a loss making company grows revenue, it can fail to deliver for shareholders.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

We regret to report that Avalo Therapeutics shareholders are down 86% for the year. Unfortunately, that's worse than the broader market decline of 20%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 1.7% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - Avalo Therapeutics has 5 warning signs (and 1 which is potentially serious) we think you should know about.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.